Cidara

CDTX NASDAQ
1.430
+0.020
+1.42%
Closed 16:00 08/23 EDT
Open
1.400
Prev Close
1.410
High
1.480
Low
1.400
Volume
24.88K
Avg Vol (3M)
137.66K
52 Week High
4.950
52 Week Low
1.223
% Turnover
0.09%
Market Cap
38.28M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Cidara CDTX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.
MORE >

Recently

Name
Price
%Change